CURE was on site at the 2025 ASH Annual Meeting, sharing expert conversations and patient-focused reporting that highlighted progress in blood cancer care. The 2025 American Society of Hematology ...
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this ...
Geron Corporation (NASDAQ:GERN) is one of the best long-term penny stocks to invest in. Geron Corporation (NASDAQ:GERN) announced on December 8 that new data was presented at the 67th American Society ...
The meeting will highlight bispecific antibodies and "off the shelf" CAR T-cell therapies, potentially transforming treatment paradigms. Fixed-duration therapies are gaining attention for their ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. The updated ...
New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster ...
Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...
As a hematologist with a keen interest in multiple myeloma who’s looking forward to the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition in December, I’ve picked out this list ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results